🔬Designer Protein Therapies Enter Human Trials in China
Chinese trials test gene therapy to suppress neuronal activity
TL;DR
Clinical trials in China are testing DREADDs, a gene therapy that uses designer receptors to turn down neuronal activity. The technology offers precise control with reduced side effects compared to traditional approaches.
Chinese researchers have initiated the first human clinical trials of DREADDs, a gene therapy designed to suppress neuronal activity by introducing designer receptors into specific brain circuits. This marks a significant step in translating decades-old chemogenetic research into potential treatments for neurological disorders like epilepsy and Parkinson's disease. The trials aim to validate the safety and efficacy of using adeno-associated viruses as vectors to deliver DREADD genes, which could revolutionize circuit-based therapeutics if successful. Trials are underway for conditions ranging from intractable epilepsy to neuropathic pain, with a focus on trigeminal neuropathic pain due to its debilitating nature.
Key Points
Seven clinical trials in China are testing chemogenetic technology based on designer receptors activated by designer drugs (DREADDs).
The DREADD receptor used binds clozapine, a drug treating schizophrenia, with picomolar affinity, ensuring high specificity and precision.
Trials began months after the first epilepsy study started, focusing on conditions like intractable epilepsy, Parkinson's disease, and neuropathic pain.
Three trials use adeno-associated viruses as vectors to deliver DREADD genes, carrying risks of immune reactions but offering precise control over neuronal activity.
If successful, these trials could pave the way for circuit-based therapeutics addressing virtually all neuropsychiatric diseases.
Why It Matters
The Chinese clinical trials testing DREADDs offer a new approach to treating neurological disorders with precise gene therapy. For researchers and clinicians focusing on epilepsy or neuropathic pain, this technology promises reduced side effects compared to traditional treatments.
Frequently Asked Questions
Why does this matter?
The Chinese clinical trials testing DREADDs offer a new approach to treating neurological disorders with precise gene therapy. For researchers and clinicians focusing on epilepsy or neuropathic pain, this technology promises reduced side effects compared to traditional treatments.
What happened?
Clinical trials in China are testing DREADDs, a gene therapy that uses designer receptors to turn down neuronal activity. The technology offers precise control with reduced side effects compared to traditional approaches.
Comments
Be the first to comment
Enjoyed this article?
Get it daily. 7am. Free. Reads in 5 minutes.
Join 3,303 builders reading daily.